Chicago, Illinois, USA, October 15, 2026
SimBioSys, an artificial intelligence-driven precision medicine company, has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for TumorSight® Risk, an AI-powered software tool designed to estimate the risk of breast cancer recurrence over five and ten years. The technology combines routinely collected breast magnetic resonance imaging (MRI), pathology and clinical data to provide individualized prognostic information for clinicians treating patients with early-stage breast cancer. The software is intended for adult women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), Stage I–IIIA breast cancer. The clearance marks a development in AI-assisted oncology, where imaging-derived information may complement conventional clinical and pathological assessments to support treatment planning.
TumorSight Risk Uses AI to Estimate Cancer Recurrence
TumorSight Risk applies proprietary spatial artificial intelligence modeling to evaluate tumor characteristics, surrounding tissue context and relevant clinical factors. The cloud-based software generates a proprietary TumorSight Risk score ranging from 0 to 100 and categorizes patients into low-, intermediate- or high-risk groups. It also provides estimates of breast cancer recurrence risk at five and ten years after diagnosis. The software incorporates dynamic contrast-enhanced MRI (DCE-MRI) data alongside clinical information, including age, race, cancer stage, lymph node status and tumor grade. By combining these different data sources, the platform is designed to provide a more individualized assessment than relying on a single clinical or imaging feature. According to SimBioSys, TumorSight Risk uses information already collected during routine care and does not require an additional procedure, tissue shipment or specialized hardware. The company says results can be made available within existing clinical workflows, potentially giving physicians prognostic information earlier in the treatment pathway. The tool is intended to support physicians’ risk-based decisions alongside other relevant clinicopathological factors; it does not independently determine a patient’s treatment.
Clinical Validation Shows Differences in Recurrence Risk
The FDA clearance was supported by a blinded, multi-institutional validation study involving 2,129 patients. The retrospective analysis included patients from Mayo Clinic, Emory University, Stanford Medicine and Mercy Medical Cedar Rapids. Study findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. According to the reported results, patients classified in the high-risk group had a 3.3-fold higher risk of recurrence than those classified in the low-risk group. Each 10-point increase in the TumorSight Risk score was associated with a 22% increase in relative recurrence risk. These findings indicate that the score differentiated patients with different observed recurrence outcomes in the evaluated population. The study also reported differences in estimated recurrence risk across score groups. For patients with scores of 0–10, estimated five-year recurrence risk was 2.2%, compared with 13.6% among patients scoring 58–100. At ten years, the corresponding estimates ranged from 6.2% to 34.2%. The association between the score and recurrence-free survival remained statistically significant after adjustment for established prognostic factors, including tumor and nodal stage, grade, age, race and treatment. These results are encouraging, but they should be interpreted in the context of the study design and population. Retrospective validation findings do not guarantee an individual patient’s outcome, and additional clinical experience may help clarify how the tool performs across different patient groups and care settings.
Advertisement
FDA Clearance Advances AI-Assisted Precision Oncology
The FDA’s 510(k) decision indicates that TumorSight Risk was found substantially equivalent to a legally marketed predicate device for its intended use. This is medical-device clearance, not FDA approval of a drug or cancer treatment. It allows the software to be marketed for its cleared intended use in the United States. TumorSight Risk builds on SimBioSys’ existing TumorSight Viz platform, which supports breast MRI visualization and analysis. The new software extends the company’s imaging technology into prognostic risk assessment, aiming to help clinicians incorporate information from medical images into individualized care planning. Breast cancer recurrence assessment commonly considers tumor characteristics, lymph node involvement, pathology findings and, in some cases, tissue-based genomic tests. An imaging-derived tool may offer an additional source of information, but its output should be considered alongside established clinical evidence, patient preferences and other appropriate assessments. SimBioSys’ FDA clearance represents a step forward for AI-assisted breast cancer risk assessment. Its practical clinical value will depend on how effectively TumorSight Risk complements existing methods and supports informed decisions between physicians and patients.
Source: SimBioSys press release
